The tumor suppressor ING4 has been shown to be reduced in human HCC. The alteration of ING4 contributes to HCC progression. However, its effect in HCC and the potential mechanism is largely unclear. Herein, we found that downregulation of ING4 in HCC tumor tissues was closely associated with cancer staging, tumor size and vascular invasion. Lentivirus-mediated ING4 overexpression significantly inhibited proliferation, migration and invasion, and induced cell cycle G1 phase arrest and apoptosis in MHCC97H human HCC cells. Moreover, overexpression of ING4 dramatically suppressed MHCC97H tumor cell growth and metastasis to lung in vivo in athymic BALB/c nude mice. Mechanistic studies revealed that overexpression of ING4 markedly increased expression of FOXO3a both at the mRNA and protein level as well as enhanced nuclear level and transcriptional activity of FOXO3a in MHCC97H tumor cells. In addition, ING4 repressed transcriptional activity of NF-κB and expression of miR-155 targeting FOXO3a. Knockdown of ING4 exhibited opposing effects in MHCC97L human HCC cells. Interestingly, knockdown of FOXO3a attenuated not only ING4-elicited tumor suppression but also ING4-mediated regulatory effect on FOXO3a downstream targets, confirming that FOXO3a is involved in ING4-directed tumor-inhibitory effect in HCC. Overexpression of miR-155 attenuated ING4-induced upregulation of FOXO3a, whereas inhibition of miR-155 blunted ING4 knockdown-induced reduction of FOXO3a. Furthermore, inhibition of NF-κB markedly impaired ING4 knockdown-induced upregulation of miR-155 and downregulation of FOXO3a. Taken together, our study provided the first compelling evidence that ING4 can suppress human HCC growth and metastasis to a great extent via a NF-κB/miR-155/FOXO3a pathway.
Introduction
HCC, a major type of primary liver cancer, is the fifth most commonly diagnosed human malignancy and the second leading cause of cancer-related mortality in the world [1] . The incidence of HCC increased dramatically worldwide especially in China during the last 20 years [2, 3] . Despite recent improvements in the diagnosis and treatment strategies for HCC, the prognosis of HCC patient is currently still far from satisfactory. The poor prognosis largely results from late detection of HCC and lack of effective therapies for advanced and recurred HCC. Alteration of signaling pathways induced by dysfunction of oncogenes and antioncogenes is one of the major pathogenic
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International Publisher mechanisms of HCC [4] . Hence, a detailed understanding of molecular mechanisms involved in the pathogenesis and progression of HCC is urgently needed, which may help to identify potential therapeutic targets and develop effective therapies for HCC.
FOXO subfamily of forkhead transcription factors, including FOXO1a/FOXO1/FKHR, FOXO3a/FOXO3/FKHRL1, FOXO4/AFX and FOXO6 four members, has been shown to participate in various biological processes such as cell cycle control, differentiation, apoptosis, stress response, DNA repair, metabolism and longevity [5, 6] . Among them, FOXO3a has been considered a bona fide tumor suppressor. Emerging evidence has demonstrated that the function of FOXO3a is inactivated by oncogenic stimuli in a broad spectrum of cancers, which is associated with carcinogenesis and cancer progression [7] [8] [9] . Activation of FOXO3a can trigger tumor cell cycle arrest and apoptosis via transcriptional activation or repression of downstream target genes implicated in regulating cell cycle and apoptosis [8] . FOXO3a also suppresses tumor angiogenesis by downregulating VEGF [10, 11] and eNOS [12] . Moreover, FOXO3a reverses tumor cell EMT and inhibits cancer metastasis through directly transactivating E-cadherin [13] as well as indirectly downregulating EMT-TFs [13] [14] [15] and β-catenin signaling [16] .
Interestingly, various anticancer therapeutics have been found to achieve their therapeutic effects through activation of FOXO3a [8, 9, 17] . FOXO3a aberration confers cancer therapy resistance and activation of FOXO3a can be effective in enhancing therapy sensitization [9, 17] . Therefore, FOXO3a represents a potential therapeutic target in human cancers.
The ING family contains ING1, ING2, ING3, ING4 and ING5 five members, belonging to the family of type Ⅱ tumor suppressor genes [18, 19] . ING4, an important member of ING family, has been found to function as a powerful tumor suppressor [20, 21] . Accumulating data has shown that ING4 function is frequently downregulated or lost by genetic/ epigenetic mechanisms and ubiquitin-mediated proteolysis in various types of human cancers, leading to cancer initiation and progression [18] [19] [20] [21] [22] . Restoration of ING4 inhibits tumor cell growth by induction of cell cycle arrest and apoptosis in a p53-dependent or -independent manner [20, 21, [23] [24] [25] . ING4 also induces tumor growth suppression via promoting toxic autophagy [26] . Of note, ING4 can enhance tumor cell sensitivity to chemotherapy [27] [28] [29] and radiotherapy [30, 31] . Additionally, ING4 suppresses tumor cell spreading, migration and invasion through interacting with liprin α1 [32] and repressing MMP-2, MMP-9 and EMT-TF Snail1 [25, 33, 34] . Furthermore, ING4 attenuates tumor angiogenesis by downregulation of IL-6 and IL-8 proangiogenic factors via inhibition of NF-κB [35] and HIF-1α pathways [36] . Thus, ING4 exhibits tumor-suppressive activities via multiple pathways.
Both FOXO3a and ING4 are downregulated in human HCC and negatively correlate with histological grade, tumor size and prognosis [37, 38] . However, the relationship of ING4 and FOXO3a, whether FOXO3a is involved in ING4-induced tumor inhibition, and related regulatory mechanism in HCC is unclear. In this study, we assessed the ING4 expression in human HCC cells and clinical tissues, examined the effects of ING4 on HCC cell growth and metastasis by lentivirus-mediated ING4 overexpression and knockdown, and elucidated the molecular mechanism.
Materials and Methods

HCC tissue samples
A total of 78 pairs of paraffin-embedded HCC tissues and adjacent non-tumor liver tissues (at least 6 cm away from the tumor) were obtained from randomly selected 78 patients who have undergone surgery and received no chemotherapy or radiotherapy at the First Affiliated Hospital of Soochow University (Suzhou, Jiangsu, China) and the Third Affiliated Hospital of the Second Military Medical University (Shanghai, China) from January 2013 to December 2015. The research was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University. Pathological staging were reviewed independently by two experienced pathologists according to the 7th edition of the AJCC Staging Manual [39] . The clinicopathological characteristics of these patients were summarized based upon medical history.
Cell lines, vectors, reagents and mice
The HL-7702 human liver cell line and the 293T human embryonic kidney cell line were purchased from the Cell Bank, Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). The MHCC97H and MHCC97L human HCC cell lines were kindly provided by Dr. Yang Xu (Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China). The above-mentioned cells were grown in DMEM (HyClone, Logan, UT, USA) supplemented with 10% FBS (Gibco, Gaithersburgh, MD, USA) and antibiotics (100 U/ml penicillin-streptomycin (Thermo Fisher Scientific, Waltham, MA, USA). The blank lentiviral plasmid pLenti6.3/IRES/GFP (BSD) and the lentiviral packing plasmids including pLP1, pLP2 and VSVG were purchased from Novobio Science & Technology (Shanghai, China). The recombinant lentiviral plasmid pLenti6.3/ING4/IRES/GFP harboring a humanized ING4 gene was constructed in our laboratory [34] . The scrambled siRNA GFP lentivirus (puromycin) (LVshcontrol) and the ING4-set siRNA/shRNA/RNAi GFP lentivirus (puromycin) (LVshING4) were purchased from abm (Richmond, BC, Canada). Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA, USA). The polybrene and the enhanced infection solution were purchased from GeneChem (Shanghai, China). The BSD was purchased from Yeasen (Shanghai, China). The puromycin was purchased from Gibco (Gaithersburgh, MD, USA). The CCK-8 was purchased from Dojindo Molecular Technologies (Gaithersburg, MD, USA). The MammoCult TM basal medium and the MammoCult TM proliferation supplement were purchased from STEMCELL Technologies (Vancouver, BC, Canada). The PI cell cycle detection kit was purchased from Nanjing KeyGen Biotechnology (Nanjing, Jiangsu, China). The Annexin-V-PE/7-AAD apoptosis detection kit was purchased from BD Biosciences (Franklin Lakes, NJ, USA). The 24-well Transwell (pore size: 8 μm), the Matrigel and the PVDF membrane were purchased from Millipore (Billerica, MA, USA). The MiniBEST universal RNA extraction kit was purchased from TaKaRa (Dalian, Liaoning, China). The RevertAid RT reverse transcription kit was purchased from Thermo Fisher Scientific (Waltham, MA, USA). The FastStart Universal SYBR Green Master (Rox) was purchased from Roche Applied Science (Penzberg, Upper Bavaria, Germany). The miScript Ⅱ RT kit, the miScript SYBR Green PCR kit and the HiPerFect transfection reagent were purchased from Qiagen (Hilden, Nordrhein-Westfalen, Germany). The primers were purchased from Sangon Biotechnology (Shanghai, China). The mammalian cell lysis kit and the nuclear extraction kit were purchased from Sigma (St Louis, MO, USA). The BCA protein assay kit was purchased from Beyotime Biotechnology (Beijing, China). The SuperEnhanced chemiluminescence detection kit was purchased from Applygen Technology (Beijing, China). Luciferase Assay System was purchased from Promega (Madison, WI, USA . The FHRE-Luc luciferase reporter plasmid was purchased from addgene (Cambridge, MA, USA). The TCF/LEF1-Luc and NF-κB-Luc luciferase reporter plasmids were purchased from Genomeditech (Shanghai, China). The 5'-DIG-and 3'-DIG-labeled miR-155 miRCURY LNA Detection probe was purchased from Exiqon (Vedbaek, Denmark). The FOXO3a (FKHRL1) siRNA and the control siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The miR-155 mimics and miRNA mimics NC and the miR-155 inhibitor and miRNA inhibitor NC were purchased from RiboBio (Guangzhou, Guangdong, China). NF-κB inhibitor JSH-23 was purchased from Selleck Chemicals (Houston, TX, USA). The 4-week-old female athymic BALB/c nude mice were purchased from Shanghai Laboratory Animal Center (Shanghai, China) and maintained in the animal facility at Soochow University (Suzhou, Jiangsu, China) according to the animal research committee's guidelines of Soochow University.
Preparation of lentiviruses
The LVING4 lentivirus expressing humanized ING4 and GFP and the LV blank lentivirus (used as a control) were prepared as previously reported [34] . The biological titer (TU/ml) of lentiviruses was assessed by calculating the number of GFP-expressing 293T cells after lentiviral infection under fluorescence microscopy. The ratio of infectious lentivirus (TU) to target cells is called MOI.
Generation of stable cell lines
The MHCC97H human HCC cells were infected with LVING4 or LV at a MOI of 20 plus 10 μg/ml of polybrene in enhanced infection solution in a 24-well culture plate. The MHCC97L human HCC cells were infected with LVshING4 or LVshcontrol as described above. 72 hours after infection, the MHCC97H cells were selected with 10 μg/ml of BSD, whereas the MHCC97L cells were selected with 2 μg/ml of puromycin. The transgene efficiency of BSD-resistant MHCC97H including MHCC97H-LVING4 (termed MHCC97H-ING4) and MHCC97H-LV (termed MHCC97H-mock, used as a control), and puromycin-resistant MHCC97L including MHCC97L-LVshING4 (termed MHCC97L-shING4) and MHCC97L-LVshcontrol (termed MHCC97L-shcontrol, used as a control) cell derivatives were detected by fluorescence microscopic and flow cytometric analysis of GFP, respectively. The overexpression and knockdown efficiency of ING4 was further analyzed by Western blot.
CCK-8 assay
The ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and the corresponding control cells were seeded at a density of 1×10 4 cells/200 μl culture medium per well in 96-well culture plates. Cell proliferation ability was evaluated at day 1, 2, 3 and 4 after cell culture using a CCK-8 according to the company's protocols. The OD of each well was measured at 450 nm in an automatic microplate reader. Cell growth curves were plotted with OD value vs culture time.
Colony formation assay
The ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and the corresponding control cells were dispensed into 6-well culture plates at a density of 200 cells/2 ml culture medium per well. After 2 weeks' incubation, the colonies were fixed with 4% paraformaldehyde and stained by crystal violet. The clonogenic ability of tumor cells was then analyzed.
Tumor sphere assay
The ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and the corresponding control cells were seeded at a density of 4×10 3 cells/2 ml complete MammoCult TM medium (MammoCult TM basal medium plus 10% MammoCult TM proliferation supplement) per well into 6-well ultra-low adherent plates. One week after incubation, the number of tumor spheres was counted.
Cell cycle analysis
The ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and the corresponding control cells were cultured, harvested, washed and fixed in ice-cold 70% ethanol at 4 o C overnight. They were then washed, treated with 500 U/ml RNase A at 37 o C for 30 min and stained with 50 μg/ml PI in the dark for 30 min. Finally, the cells were washed and the cell cycle profiles were analyzed by flow cytometry.
Annexin-V-PE/7-AAD apoptosis assay
The ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and the corresponding control cells were cultured, collected, washed and resuspended in 1×Annexin V binding buffer at a density of 1×10 5 cells/100 μl. The 100 μl each of above cell suspension were then incubated with Annexin V-PE (5 μl) and 7-AAD (5 μl) at room temperature for 15 minutes and analyzed by flow cytometry.
Transwell migration and invasion assays
In a Transwell migration assay, the ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and the corresponding control cells (2×10 4 cells/100 μl serum-free DMEM medium) were directly added to the upper chamber of 24-well/8 μm pore size Transwell filters. In a Transwell invasion assay, the above cells (2×10 5 cells/100 μl serum-free DMEM medium) were seeded onto the upper chamber of Transwell filters which were precoated with Matrigel. The lower chamber was filled with 500 μL of DMEM medium supplemented with 20% FBS. After 24 hours of incubation, tumor cells on the upper surface of filter were removed and cells migrating or invading into the bottom side of insert were fixed by 4% paraformaldehyde, stained with crystal violet, photographed and counted in 5 randomly selected ×200 high-power fields by other investigators that were blinded to the group allocation. The migratory and invasive ability of tumor cells was then analyzed.
Xenograft mouse models
The BALB/c nude mice were subcutaneously inoculated with ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and corresponding control cells (2×10 6 cells/100 μl PBS/mouse) (6 mice/group). Tumor growth in vivo was monitored by other investigators that were blinded to the group allocation. Tumor volume was measured with a caliper and calculated by the formula, tumor size=ab 2 /2, where a is the larger of the two dimensions and b is the smaller. The tumor-bearing mice were sacrificed 4 weeks after tumor cell inoculation and the xenografted tumors were then removed and weighted. In another in vivo lung metastasis model, the nude mice (6 mice/group) were intravenously injected with the above-mentioned cells (2×10 6 cells/200 μl PBS/mouse) through tail vein. The mice were killed 4 weeks after tumor cell injection and the lung tissues were removed, fixed in 10% neutral formalin and embedded in paraffin. The lung metastasis nodules of HCC were analyzed by HE staining. The tumor metastasis nodules were then counted by other investigators that were blinded to the group allocation at 5 randomly selected ×40 low-power fields of each section under microscopy.
Western blot analysis
For preparation of total proteins, the HL-7702, MHCC97H and MHCC97L cells; and the ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and corresponding control cells (1×10 7 cells/1 ml lysis buffer) were lysed in lysis buffer supplemented with a protease inhibitor cocktail using a mammalian cell lysis kit. The nuclear proteins derived from ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and corresponding control cells were isolated using a nuclear extraction kit. The protein concentrations were measured by a BCA protein assay kit. The lysates were loaded (50 µg/lane) and separated in 12% SDS-PAGE and transferred to PVDF membranes. The membranes were then blocked with 5% fat-free milk in PBS containing 0.1% Tween-20. The membranes transferred by total lysates derived from HL-7702, MHCC97H and MHCC97L cells were subsequently incubated with a primary antibody anti-ING4 (1:1000) or anti-β-actin (1:1000) (used as a loading control) at 4 o C overnight. The membranes transferred by total lysates derived from ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and corresponding control cells were incubated with primary antibodies including anti-ING4 (1:1000), anti-FOXO3a (1:1000), anti-p27 (1:1000), anti-Cyclin D1 (1:1000), anti-Bim (1:1000), anti-Puma (1:1000), anti-FasL (1:1000), anti-TRAIL (1:1000), anti-β-catenin (1:1000), anti-NF-κB p65 (1:1000), anti-NF-κB p105/p50 (1:1000) and anti-β-actin (1:1000) (used as a loading control), respectively. The membranes transferred by nuclear lysates were incubated with primary antibodies including anti-FOXO3a (1:1000), anti-β-catenin (1:1000), anti-NF-κB p65 (1:1000), anti-NF-κB p105/p50 (1:1000) and Histone H3 (1:1000) (used as a loading control), respectively. Followed by incubation with a secondary antibody HRP-conjugated anti-rabbit IgG (CST, 1:3000) for 1 hour, the protein signaling on the membranes was detected using a SuperEnhanced chemiluminescence detection kit and the protein bands were then visualized after their exposure to X-ray films.
Real-time qRT-PCR analysis
The total RNAs of ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and corresponding control cells (2×10 6 cells) were extracted using a MiniBEST universal RNA extraction kit. The RNAs were reversely transcribed to first-strand cDNAs by a RevertAid RT reverse transcription kit and a miScript Ⅱ RT kit, respectively. The RevertAid RT-derived cDNAs were then subjected to qPCR analysis of transcriptional expression of FOXO3a (FOXO3a-F: 5'-TCT TCA GGT CCT CCT GTT CCT G-3' and FOXO3a-R: 5'-GGA AGC ACC AAA GAA GAG AGA AG-3' for amplifying 132 bp) using a FastStart Universal SYBR Green Master (Rox) following manufacturer's instructions. The β-actin (β-actin-F: 5'-CTC ACC ATG GAT GAT GAT ATC GC-3' and β-actin-R: 5'-AGG AAT CCT TCT GAC CCA TGC-3' for amplifying 163 bp) was used an internal control. The miScript Ⅱ RT-derived cDNAs were subjected to qPCR analysis of expression of miR-96, miR-155, miR-182, miR-551b and miR-592 (U6 used as an internal control) using a miScript SYBR Green PCR kit following company's protocols. The expression level was normalized to the internal control and calculated by a 2 -∆∆CT method as previously described [40] .
Luciferase reporter assays
The ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and corresponding control cells were transfected with FHRE-Luc, TCF/LEF1-Luc and NF-κB-Luc luciferase reporter plasmids using Lipofectamine 2000, respectively. 48 hours after transfection, the cells were harvested, lysed and luciferase activity was detected by a Luciferase Assay System according to manufacturer's instructions. The effect of ING4 on the transcriptional activity of FOXO3a, β-catenin and NF-κB in HCC cells was then analyzed.
FOXO3a siRNA knockdown assay
The MHCC97H-ING4 HCC cells were transfected with 100 nM human FOXO3a siRNA (siFOXO3a) or control siRNA (sicontrol) using a HiPerFect transfection reagent following company's instructions. After 48 hours of transfection, the siFOXO3a-or sicontrol-transfected MHCC97H-ING4 cells and the untransfected MHCC97H-ING4 or MHCC97H-mock cells were then subjected to in vitro and in vivo functional assays as well as Western blot analysis of FOXO3a, p27, Cyclin D1, Bim, Puma, FasL, TRAIL and β-catenin. 
MiR-155 mimics/inhibitor assay
NF-κB inhibition assay
The MHCC97L-shING4 HCC cells were pretreated with NF-κB inhibitor JSH-23 (10 μM) or DMSO without JSH-23 in culture medium for 1 hour. Then the JSH-23-treated and DMSO-treated MHCC97L-shING4 cells and the untreated MHCC97L-shING4 and MHCC97L-shcontrol cells were cultured in fresh culture medium. After another 48 hours of incubation, the above cells were subjected to qRT-PCR analysis of miR-155 and FOXO3a, respectively.
Immunohistochemistry and in situ hybridization analyses
The above formalin-fixed and paraffinembedded HCC and adjacent non-tumor liver tissue samples were cut into 4 μm-thick sections, respectively. The sections were then deparaffinized, rehydrated, microaved in 0.01 M citrate buffer (pH=6.0) for antigen retrieval, treated with 3% H 2 O 2 for quenching of endogenous peroxidase activity, and then blocked with goat serum. Subsequently, the sections were incubated with rabbit anti-ING4 (1:25), anti-FOXO3a (1:200) or anti-NF-κB p65 (1:100) primary antibody in a humidity chamber overnight at 4 o C. HRP-conjugated anti-rabbit IgG secondary antibody (Boster, 1:1000) was then incubated for 1 hour at room temperature and immunostaining signal was detected by DAB. Finally, the slides were counterstained with HE and coverslipped. The percentage of positive tumor cells and the intensity of immunostaining were used to gain the IHC scoring, respectively. The percentage of positive tumor cells was assigned to 5 categories: ≤5% (0), 5-25% (1), 25-50% (2), 50-75% (3), and ≥75% (4). The staining intensity was scored as follows: negative (0), weak (1), moderate (2) , and strong (3). The percentage of positive tumor cells and the staining intensity were then added to produce a weighted score for each specimen. The IHC scores were finally grouped as (-), 0-1; (+), 2-3; (++), 4-5; and (+++), 6-7. It was considered as high expression when the final weighted scores were ≥4 (++, +++). In addition, the expression of miR-155 in the sections were analyzed by in situ hybridization using 5'-DIG-and 3'-DIG-labeled miR-155 miRCURY LNA Detection probe (50 nM) according to company's instructions. After hybridization, the sections were incubated with AP-conjugated anti-DIG antibody (1:400) followed by reaction with BCIP/NBT. The signal of hybridization was then analyzed.
Statistical analyses
All statistical analyses were carried out with Mann-Whitney U test, Pearson's χ 2 test, Student t test and one-way or two-way repeated measures analysis of variance (ANOVA) using SPSS13.0 software (SPSS, Chicago, IL, USA). A value of p<0.05 was considered statistically significant.
Results
ING4 is reduced in human HCC and correlated with clinicopathological features of HCC
Immunohistochemistry analysis of 78 paired paraffin-embedded human HCC and adjacent non-tumor clinical tissue sections (Figure 1) showed that low expression of ING4 in tumor tissues occurred in 55 cases (37 cases scored "-" and 18 cases scored "+") (70.5%), whereas high expression of ING4 only occurred in 23 cases (12 cases scored "++" and 11 cases scored "+++") (29.5%). Among matched adjacent non-tumor tissues, 61 cases (78.2%) displayed high expression of ING4 (25 cases scored "++" and 36 cases scored "+++"), while 17 cases (21.8%) exhibited low expression of ING4 (1 case scored "-" and 16 cases scored "+"). Consistent with a previous report [38] , our results demonstrated that the expression of ING4 in HCC tumor tissues was significantly lower than that in adjacent normal tissues (p<0.05). On the basis of ING4 expression in HCC tumor tissues, 78 patients with HCC were divided into two groups: low-expression group ("-" or "+", n=55) and high-expression group ("++" or "+++", n=23 
Lentivirus-mediated ING4 overexpression or knockdown in HCC cells
To generate ING4-overexpressed/silenced stable HCC cell lines for functional studies, we measured the expression level of ING4 in MHCC97H and MHCC97L human HCC cell lines. Among them, MHCC97H is a highly malignant and metastatic HCC cell line whose genetic background is similar to a relative low-metastasis HCC cell line MHCC97L [41] . Compared with HL-7702 immortal non-cancerous human liver cell line control, the expression of ING4 is significantly downregulated in MHCC97H and MHCC97L HCC cell lines (Figure 2A ) (p<0.05). Notably, ING4 was detected at a lower level in MHCC97H cell line than MHCC97L cell line Figure 2C , the MHCC97H HCC cells showed a marked increase in the expression of ING4 after lentivirus-directed ING4 gene transfer, whereas the MHCC97L HCC cells displayed a remarkable reduction in the expression of ING4 after transduced by ING4 shRNA compared with that transduced by shcontrol (p<0.05). Our results revealed that lentivirus-mediated ING4-transgenic MHCC97H and ING4-silenced MHCC97L HCC cell lines were successfully generated.
ING4 inhibits HCC cell growth and induces cell cycle G1 phase arrest and apoptosis
To examine the effect of ING4 on human HCC cell growth, the in vitro proliferation ability of MHCC97H-ING4 vs MHCC97H-mock and MHCC97L-shING4 vs MHCC97L-shcontrol tumor cells was determined by a CCK-8 assay. As shown in Figure 3A , the growth curve in the MHCC97H-ING4 group was much lower than that in the LV-transduced MHCC97H-mock control group As shown in Figure 3D-F Figure 3G , overexpression of ING4 impeded the entry of G1 to S phase and induced G1 phase arrest in MHCC97H tumor cells, whereas knockdown of ING4 induced a reduction of cells on G1 phase as well as an accumulation of cells on S phase in MHCC97L tumor cells (p<0.05). Furthermore, forced expression of ING4 obviously induced apoptosis in MHCC97H tumor cells ( Figure  3H ) (p<0.05). Additionally, knockdown of ING4 could induce resistance of MHCC97L tumor cells to apoptosis in a serum-starved condition ( Figure 3H ) (p<0.05). Taking these results together, ING4 can suppress HCC cell growth via inhibition of cell cycle G1 to S phase transition and induction of apoptosis.
ING4 suppresses HCC cell migration, invasion and distant lung metastasis
To analyze the association of ING4 with metastatic potential of HCC cells, Transwell chamber migration and invasion assays were conducted to examine the in vitro migratory and invasive ability of MHCC97H-ING4 vs MHCC97H-mock and MHCC97L-shING4 vs MHCC97L-shcontrol tumor cells. As shown in Figure 4A and B, the migratory capacity of MHCC97H-ING4 tumor cells was dramatically impaired compared with MHCC97H-mock control group (p<0.05). Knockdown of ING4 significantly boosted the migration of MHCC97L tumor cells ( Figure 4A and B) (p<0.05). Moreover, lentivirus-mediated ING4 overexpression suppressed MHCC97H tumor cell invasion, whereas its knockdown promoted the process in MHCC97L tumor cells ( Figure 4C and D) (p<0.05). To further wonder whether the correlation between ING4 expression and HCC metastatic traits in vitro could be reproduced in vivo, the ING4-overexpressed MHCC97H or ING4-silenced MHCC97L HCC cells and corresponding control cells were injected into the tail vein of athymic BALB/c nude mice. Four weeks after intravenous injection, the lung tissues of mice were removed and the lung metastasis was assessed by HE analysis. As shown in Figure 4E and F, the MHCC97H-ING4 tumor cells exhibited a significant decrease in tumor lung metastasis nodule compared with MHCC97H-mock control cells, while MHCC97L-shING4 tumor cells had much higher metastatic ability in vivo than MHCC97L-shcontrol control cells (p<0.05). These data indicated that ING4 efficiently weakens the metastasis potential of HCC cells.
ING4 represses HCC growth and metastasis via upregulation of FOXO3a
It has been generally recognized that FOXO3a functions as an important negative mediator of HCC progression [37, 42] . To address the potential mechanism responsible for ING4-induced inhibition of growth and metastasis in HCC cells, we thus asked whether FOXO3a is involved in ING4-mediated tumorsuppressive effects. Western blot analysis ( Figure 5A and B) showed that compared to MHCC97H-mock control group, both the total and the nuclear levels of FOXO3a were dramatically increased in MHCC97H-ING4 group (p<0.05). Conversely, the total and nuclear levels of FOXO3a were reduced in MHCC97L-shING4 group compared with MHCC97L-shcontrol control group ( Figure 5A and B) (p<0.05). qRT-PCR analysis ( Figure 5C ) also demonstrated that forced expression of ING4 upregulated the level of FOXO3a mRNA in MHCC97H HCC cells, whereas knockdown of ING4 downregulated it in MHCC97L HCC cells (p<0.05). Luciferase reporter assay further showed that ING4 significantly enhanced the transcriptional activity of FOXO3a ( Figure 5D ) (p<0.05). In addition, we found that overexpression of ING4 upregulated the expression of FOXO3a's transactive targets [8] such as p27, Bim, Puma, FasL and TRAIL as well as downregulated the expression of FOXO3a's transrepressive target Cyclin D1 [8] in MHCC97H HCC cells, whereas knockdown of ING4 displayed opposing regulatory effects in MHCC97L HCC cells ( Figure 5A ). Moreover, ING4 inhibited the total/nuclear expression ( Figure  5A ) and transcriptional activity ( Figure 5D ) of another FOXO3a's target β-catenin [16] 
ING4 upregulates FOXO3a via a NF-κB/miR-155 pathway
Accumulating evidence [43] [44] [45] [46] [47] has documented that several miRNAs such as miR-96, miR-155, miR-182, miR-551b and miR-592 target FOXO3a. To address the molecular mechanism by which ING4 regulates FOXO3a and elucidate whether miRNAs targeting FOXO3a are involved in ING4-mediated regulation of FOXO3a, we analyzed the expression of above miRNAs in MHCC97H-ING4  vs  MHCC97H-mock  and  MHCC97L-shING4 MiR-155 as a well-known NF-κB downstream target has been found to be positively regulated by a NF-κB pathway [44] . Western blot analysis of NF-κB p65 and p50. The representative pictures of Western blot were shown. E. Luciferase reporter analysis of transcriptional activity of NF-κB. The luciferase activity was expressed as a ratio or fold of MHCC97H-mock or MHCC97L-shcontrol control, with 1 being the value for controls. MHCC97H: *, p<0.05 compared with MHCC97H-mock; MHCC97L: *, p<0.05 compared with MHCC97L-shcontrol, Student t test, n=6 replicates per sample. F. Real-time qRT-PCR analysis of miR-155 after NF-κB inhibition. The expression level of miR-155 was normalized to U6 and calculated by a 2 -∆∆CT method, with 1 being the value for MHCC97L-shcontrol. *, p<0.05 compared with MHCC97L-shING4 and DMSO-treated MHCC97L-shING4, one-way repeated measures ANOVA, n=6 replicates per sample. G. Real-time qRT-PCR analysis of FOXO3a after NF-κB inhibition. The mRNA level of FOXO3a was normalized to β-actin and calculated by a 2 -∆∆CT method, with 1 being the value for MHCC97L-shcontrol. *, p<0.05 compared with MHCC97L-shING4 and DMSO-treated MHCC97L-shING4, one-way repeated measures ANOVA, n=6 replicates per sample. Data shown were representative of three independent experiments. ING4 has been shown to inhibit the transcriptional activity of NF-κB [35, 48, 49] . To confirm whether ING4 regulates miR-155 via a NF-κB pathway, we firstly analyzed the effect of ING4 on the expression of NF-κB p65/p50 and the transcriptional activity of NF-κB by Western blot and luciferase reporter assays. As shown in Figure 6D 
Discussion
The present study demonstrated that ING4 is dramatically reduced in human HCC and its expression level is inversely associated with AJCC cancer staging, tumor size and vascular invasion. Forced expression of ING4 not only significantly suppresses HCC cell proliferation, migration and invasion, and induces HCC cell apoptosis in vitro but also retards HCC subcutaneously xenografted tumor growth and distant lung metastasis in vivo in nude mice via upregulating FOXO3a and modulating its downstream targets, whereas knockdown of ING4 exerts opposing effects. Moreover, ING4 increases the expression and the transcriptional activity of FOXO3a by inhibition of NF-κB/miR-155 pathway.
It has been reported that FOXO3a is a promising therapeutic target for human HCC and various toxic compounds exhibits tumor-suppressive effects in HCC via FOXO3a activation [42, 50] . To decipher the underlying mechanism by which ING4 suppresses HCC, we was thus interested in examining whether FOXO3a is involved in ING4-medicated tumor inhibition in HCC. Our results showed that ING4 obviously upregulated expression of FOXO3a in HCC cells both at mRNA and total/nuclear protein level, whereas knockdown of ING4 downregulated it. Luciferase reporter assay further demonstrated that ING4 enhanced the transcription activity of FOXO3a. Previous studies showed that FOXO3a induces cell cycle arrest and apoptosis by regulating target genes such as p27, Cyclin D1, Bim, Puma, FasL and TRAIL [8] . Previous studies also showed that FOXO3a impedes cancer metastasis via inactivation of β-catenin signaling by indirect transactivation of miR-34b/c targeting β-catenin [16] or direct transcriptional inhibition of β-catenin [51] . In addition, FOXO3a can directly bind to β-catenin and compete with TCF for interaction with β-catenin, therefore inhibiting β-catenin signaling [16, 52] . As we expected, ING4 upregulated p27, Bim, Puma, FasL and TRAIL expression as well as downregulated Cyclin D1 expression and β-catenin signaling in HCC cells. Furthermore, knockdown of FOXO3a could significantly impair the ING4-induced tumor suppression and the ING4-medicated regulatory effect on downstream targets of FOXO3a. Our data indicated that ING4 suppresses HCC growth and metastasis in a FOXO3a-dependent fashion.
The expression and transcriptional activity of FOXO3a is regulated by at multilayer levels such as transcription, post-transcription and post-translation modifications [6, 8] . miRNAs negatively regulates gene expression at a post-transcriptional level by interacting with sequences within the 3'-UTR of the target mRNA. A panel of miRNAs including miR-96, miR-155, miR-182, miR-551b and miR-592 has been shown to target FOXO3a [43] [44] [45] [46] [47] . Our data found that ING4 could increase the mRNA level of FOXO3a in HCC cells, which promoted us to investigate whether ING4 upregulates FOXO3a via downregulation of above miRNAs targeting FOXO3a. Interestingly, qRT-PCR analysis revealed that ING4 efficiently inhibited the expression of miR-155 in HCC cells, whereas knockdown of ING4 increased the expression of miR-155. Moreover, restoration of miR-155 significantly attenuated ING4-mediated upregulation of FOXO3a (mRNA and protein). Inhibition of miR-155 blocked the effect on decrease of FOXO3a induced by ING4 knockdown. These results suggested that ING4 upregulates FOXO3a in HCC cells via inhibiting miR-155 expression and preventing miR-155-mediated degradation of FOXO3a mRNA. It has also been shown that FOXO3a is negatively regulated via phosphorylation by AKT (Thr32, Ser253 and Ser315) [53, 54] , ERK (Ser294, Ser344 and Ser425) [55] and IKKβ (Ser644) [56] kinases. Phosphorylation of FOXO3a induces its nuclear exclusion, sequestration in the cytosol and degradation through the ubiquitin-proteasome pathway, thereby inhibiting the transcriptional activity of FOXO3a [53] [54] [55] [56] . MiR-155 has been reported to upregulate PI3K/AKT signaling by targeting PTEN [57, 58] . Therefore, whether post-translational regulation of FOXO3a, elicited by ING4-mediated inhibition of PI3K/AKT signaling via upregulating PTEN through inhibiting miR-155, is also implicated in ING4-directed upregulation of FOXO3a needs further investigation. Previous studies has shown that ING4 can inhibit the transcriptional activity of NF-κB by a chromatin-remolding manner and a ubiqutin-mediated degradation of NF-κB p65 [35, 48, 49] . MiR-155 as an oncomiRNA has been found to be positively regulated by NF-κB pathway [44, 59, 60] . To further address whether ING4 regulates miR-155 via a NF-κB pathway, we determined the effect of ING4 on NF-κB in HCC cells. Consistent with previous findings, we found that ING4 did repress the activation of NF-κB in HCC cells, whereas knockdown of ING4 enhanced its activation. Furthermore, inhibition of NF-κB markedly impaired the ING4 knockdown-induced upregulation of miR-155 and downregulation of FOXO3a. Our data implied that ING4 suppresses miR-155 expression and upregulates FOXO3a expression in HCC cells via inactivating NF-κB pathway.
Taken together, our study provided the first compelling evidence that ING4 can suppress human HCC growth and metastasis to a great extent via a NF-κB/miR-155/FOXO3a pathway. Downregulation of ING4 in human HCC may facilitate the activation of NF-κB, upregulation of miR-155 and downregulation of FOXO3a, leading to HCC progression.
